UDP-glucose ceramide glucosyltransferase (UGCG) (UGCG)

UDP-glucose ceramide glucosyltransferase (UGCG), commonly referred to as glucosylceramide synthase (GCS), is a membrane-bound enzyme localized to the Golgi apparatus [3, 10]. It catalyzes the transfer of a glucose residue from UDP-glucose to ceramide, which is the initial and rate-limiting step in the biosynthesis of most glycosphingolipids [2, 7]. This enzyme plays a central role in maintaining sphingolipid balance by regulating the levels of pro-apoptotic ceramide and its non-toxic glycosylated products [1, 11]. In clinical medicine, UGCG is a primary target for Substrate Reduction Therapy (SRT) in lysosomal storage disorders such as Gaucher and Fabry diseases, where inhibitors are used to prevent the toxic accumulation of sphingolipid substrates [4, 6, 7]. Beyond metabolic disorders, UGCG is significantly overexpressed in various cancers, where it contributes to multidrug resistance by neutralizing ceramide-induced cell death and promoting drug efflux through pathways involving MDR1 [2, 10, 13]. Current pharmacological agents targeting this enzyme include approved drugs like miglustat and eliglustat, as well as novel inhibitors in clinical development for neurodegenerative conditions [1, 4, 9].

Other names

Glucosylceramide synthaseGCSCeramide glucosyltransferaseUDP-glucose:N-acylsphingosine D-glucosyltransferaseUDP-glucose:ceramide glucosyltransferaseGLCT-1

Substrate reduction therapy (SRT) via competitive inhibition of the enzyme's active site, preventing the conversion of ceramide to glucosylceramide and thereby reducing the synthesis of complex downstream glycosphingolipids [1, 4].